Mitsubishi Tanabe Pharma Corporation

3rd Quarter of FY2012 Business Results (April – December, 2012)

February 1, 2013



Kenkichi Kosakai Board Director Managing Executive Officer

Mitsubishi Tanabe Pharma

Overview of Q3 FY2012 Business Results



Sales	¥ 322.5 billion	+2.2%, year-on-year
	•	emicade, new products and royalty, etc. llion due to the NHI drug prices revision
Operating income	¥ 58.8 billion	-1.8%, year-on-year
Net income	¥ 35.2 billion	-1.7%, year-on-year

- Growth of Remicade sales: ¥ 56.5 billion, up 10.9%, ¥ 5.5 billion
- FTY720 (Gilenya) becomes blockbuster:

Sales of \$ 1,195 million in 2012 \rightarrow MTPC royalty of ¥13.9 billion

- Growth of 6 new products sales: ¥ 16.1 billion, up ¥ 14.7 billion
- TA-7284: recommended approval by FDA Advisory Committee (Jan. 2013)
- Provision of reserve for HCV litigation: ¥ 2.0 billion

New Value Creation

Q3 FY2012 Business Results Outline

Q3 FY2012 Financial Results [April to December, 2012]

New Value Creation



	FY2012	FY2011	Increase/decrease			Full-year forecasts*	Achieved
	Billion yen	Billion yen	Billion yen	%		Billion yen	%
Net sales	322.5	315.7	+6.8	+2.2		425.0	75.9
Cost of sales	126.7	119.3	+7.4	+6.2		167.0	75.9
Sales cost ratio	39.3%	37.8%				39.3%	
Gross operation profit	195.8	196.4	-0.5	-0.3		258.0	75.9
SG&A	136.9	136.4	+0.4	+0.4		188.0	72.9
Operating income	58.8	59.9	-1.0	-1.8		70.0	84.1
Ordinary income	60.1	60.3	-0.2	-0.4		71.0	84.7
Extraordinary income&loss	-4.1	-3.3	-0.8			-5.0	83.0
Net income	35.2	35.8	-0.6	-1.7		40.5	87.0

*: Published forecasts announced on October 29, 2012 in the financial results for Q2 FY2012.

Sales by Business Segment

New Value Creation



[Q3 FY2012 Financial Results] Full-year **FY2012** FY2011 Increase/decrease Achieved forecasts % % Billion yen Billion ven Billion yen Billion yen 322.5 315.7 +2.2425.0 75.9 Net sales +6.8[31.9] [20.5] [+11.4] [+55.5] [41.0] [Overseas sales] [77.9] 318.9 308.3 +10.5+3.4420.5 75.8 **Pharmaceuticals** Ethical drugs 278.5 278.5 0.0 0.0 369.0 75.5 domestic sales Ethical drugs 15.2 13.8 +1.3 23.5 +9.864.7 overseas sales OTC 4.2 4.3 0.0 -1.9 5.5 77.8 11.5 +9.322.5 Others 20.8 +80.892.7 3.6 7.4 -3.7 -50.7 4.5 81.2 Other Businesses

Ethical Drugs Sales of Main Products

[Q3 FY2012 Financial Results]


New Value Creation



		FY2012	FY2011	Increase/o	decrease	Full-year forecasts	Achieved
		Billion yen	Billion yen	Billion yen	%		%
Ethical drugs domestic sales		278.5	278.5	0.0	0.0	369.0	75.5
	Remicade	56.5	50.9	+5.5	+10.9	75.0	75.4
Priority roducts	Maintate	10.9	10.6	+0.2	+2.7	15.0	72.9
Priority products	Kremezin	9.4	9.0	+0.4	+4.7	12.5	76.0
	Talion	8.9	9.2	-0.2	-2.7	15.0	59.8
	Telavic	4.4	0.1	+4.3	-	8.5	52.9
New	Simponi	3.7	0.4	+3.3	-	7.0	54.0
Lexapro		3.0	0.7	+2.2	-	5.5	55.9
Vaccines		23.9	24.5	-0.5	-2.2	29.5	81.3
	[Mearubik]	[6.1]	[7.4]	[-1.2]	[-17.4]	[8.0]	[77.0]
	[Influenza]	[8.3]	[8.7]	[-0.4]	[-4.9]	[8.5]	[98.1]
[JEBIK V]		[4.1]	[6.1]	[-2.0]	[-33.1]	[6.0]	[68.9]
Generics*		14.6	13.4	+1.2	+9.0	19.0	76.9
Licensing fee, etc		15.8	5.0	+10.8	+216.1	15.5	102.0
[Royalty from Gilenya]		[13.9]	[3.3]	[+10.5]	[+314.0]	[-]	[-]
*: Ge	enerics and the long-lis	sted drugs which	were transferre	d from MTPC			5

New Products Sales Trends





Telavic (Chronic Hepatitis C)

- Thorough information provision for appropriate usage
- Patient registration : 8,256 (as of Dec. 31, 2012)

Simponi (RA)

- Successful market penetration because of easy administration and high efficacy
- Used in about 7,000 patients (total of Janssen and MTPC, estimated by MTPC)

Lexapro (Depression)

- Favorable growth of sales and market share after the removal of the ban on long-term prescription in Aug. 2012
- Steady market penetration

Tenelia (Type 2 Diabetes Mellitus)

- Launched (Sep. 10, 2012)
- Strategic sales alliance with Daiichi Sankyo (total 4,000 MRs)
- Working toward prompt market penetration and expansion of its prescriptions through the alliance with Daiichi Sankyo

Tetrabik (Tetra Vaccine)

- Launched (Oct. 31, 2012)
- Routine vaccination from Nov. 1, 2012

Imusera/Gilenya





Novartis 2012 worldwide sales: about \$1.2 billion Approved in more than 65 countries Used in the treatment of more than 53,000 patients after marketing Japan The ban on long-term prescription was removed on Dec. 1, 2012 49%* increase in sales in Dec. 2012, based on drug price, month-to-month • 35%* of market share in Dec. 2012 *: total of Novartis Pharma and MTPC ©2013 IMS Japan, all rights reserved. Source: JPM(Nov.-Dec. 2012), reprinted with permission **Worldwide Sales** (USD m) **Royalty Income** (JPY b) 4.5 400 Recorded in Other than US 4 US 350 Q3 FY2012 3.5 300 3 250 2.5 200 2 150 1.5 100 1 50 0.5 0 0 Q2 Q3 Q2 Q3 Q4 01 Q4 Q1 04 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 (Oct.-Dec.) (Oct.-Dec.) 2010 2011 2012 FY2011 FY2012 Source: Novartis financial result

Cost of Sales/SG&A Expenses

New Value Creation



[Q3 FY2012 Financial Results] Full-year **FY2012** FY2011 Increase/decrease Achieved forecasts Billion yen Billion yen % Billion yen Billion yen Net sales 322.5 315.7 +6.8 425.0 +2.2

Cost of sales	126.7	119.3	+7.4	+6.2	167.0	75.9
Sales cost ratio	39.3%	37.8%			39.3%	
Gross operation profit	195.8	196.4	-0.5	-0.3	258.0	75.9
SG&A	136.9	136.4	+0.4	+0.4	188.0	72.9
R&D expenses	51.2	51.6	-0.3	-0.8	70.0	73.2
Labor costs	38.4	38.8	-0.4	-1.1	51.5	74.6
Amortization of goodwill	7.6	7.5	0.0	+1.2	10.2	75.4
Others	39.6	38.4	+1.2	+3.1	56.3	70.4
Operating income	58.8	59.9	-1.0	-1.8	70.0	84.1
						8

%

75.9

Non-operating Income and Loss/ Extraordinary Income and Loss [Q3 FY2012 Financial Results]

New Value Creation



	FY2012	FY2011	Increase/decrease		Full-year forecasts	Achieved
	Billion yen	Billion yen	Billion yen	%	Billion yen	%
Operating income	58.8	59.9	-1.0	-1.8	70.0	84.1
Non-operating income & loss	1.2	0.4	+0.8			
Ordinary income	60.1	60.3	-0.2	-0.4	71.0	84.7
Extraordinary income	1.2	-	+1.2			
Gains on sales of fixed assets	0.6	-	+0.6			
Gains on transfer of business	0.3	-	+0.3			
Extraordinary loss	5.3	3.3	+2.0			
Loss on business integration	2.2	-	+2.2			
Provision of reserve for HCV litigation	2.0	-	+2.0			
Loss on sales of investment in securities	0.3	-	+0.3			
Loss on impairment of fixed assets	0.3	2.9	-2.5			
Net income	35.2	35.8	-0.6	-1.7	40.5	87.0

New Value Creation

Development Pipeline

Progress of Development Pipeline → : Changes since Oct. 29, 2012 Mitsubishi Tanabe Pharma

New Value Creation

		Category (Indications)	Region (Licensing out partners)	P1	P2	Р3	Filed	Approved
	MCI-196/ BindRen	Non-absorbed phosphate binder (Hyperphosphatemia)	Europe					\rightarrow
	MP-424	NS3-4A protease inhibitor (Chronic hepatitis C)	Taiwan				>	
use	MT-9938	к-opioid receptor agonist (Refractory pruritus)	US		>			
In-house	MT-4666	α7nACh receptor agonist (Alzheimer's disease)	Japan	_	\rightarrow			
	MT-1303	S1P receptor functional antagonist (Multiple sclerosis)	Europe		P2 start soon			
	MT-3995	Selective mineralocorticoid receptor antagonist (Diabetic nephropathy)	Europe		P2 start soon			
out	TA-7284/ INVOKANA	SGLT2 inhibitor (Type2 diabetes mellitus)	US (Janssen Pharmaceuticals)				reco	AdCom mmended oval
Licensing-out	MCC-847	Leukotriene D4 receptor antagonist (Asthma)	Korea (SAMA Pharma)		>			
Licer	MT-4580	Ca sensing receptor agonist (Secondary hyperparathyroidism)	Japan (Kyowa Hakko Kirin)	->				11

Progress in TA-7284 and MCI-196





TA-7284 / Canagliflozin (Type 2 Diabetes Mellitus)

US, Europe: licensing-out to Janssen Pharmaceuticals

- FDA Advisory Committee recommended its approval on Jan. 10, 2013 (PDUFA: Q1, 2013)
- Trade name in US: INVOKANA
- Europe file submitted in Jun. 2012, EMA decision expected in Q3, 2013
- Fixed dose combination with metformin: US file submitted in Dec. 2012 Japan: Developed by MTPC
- Phase 3 program is ongoing
- Planning to file in 1st half of FY2013 (Apr-Sep, 2013)

MCI-196/ Colestilan (Hyperphosphatemia)

- Approved in Europe (Jan. 2013)
- Brand name : BindRen (Brand name in Japan : CHOLEBINE)
- Planning to market in Apr, 2013 in Germany by Mitsubishi Pharma Deutschland

Progress in MT-4666 and MT-9938





MT-4666 (Alzheimer's disease)

- Licensed from EnVivo
- P2 in Japan (Dec. 2012-)
- α7 nicotinic acetylcholine (α7 nACh) receptor agonist
- α7 nACh receptor is mainly expressed in cerebral cortex and hippocampus which are involved in cognition

MT-9938 (Refractory pruritus)

- Licensed from Toray
- P2 in US (Dec, 2012-)
- κ-opioid receptor agonist
- For treatment of pruritus in hemodialysis patients
- Launched for hemodialysis patients in Japan in 2009 by Toray and Torii (brand name: REMITCH)
- No psychological and physical addiction, suggested by the usage experience in Japan

Progress in MT-3995 and MT-1303





MT-3995 (Diabetic nephropathy)

- Preparing for first dosing of P2 study in Europe
- Selective mineralocorticoid receptor antagonist
- Expected to reduce hyperkalemia and side effects related to sex hormone, etc.
- P1 study is ongoing in Japan

MT-1303 (Multiple screlosis)

- Preparing for first dosing of P2 study in Europe
- Second generation of S1P receptor functional antagonist, improved safety profile
- P1 study is ongoing in Japan





New Value Creation

Becoming a "Company that Can Continue to Create New Value"



Cautionary Statement

The statements contained in this presentation is based on a number of assumptions and belief in light of the information currently available to management of the company and is subject to significant risks and uncertainties.